Serum apelin‐13 levels and total oxidant/antioxidant status of patients with Alzheimer’s disease

OBJECTIVE: We aimed to evaluate apelin‐13 levels, total oxidant/antioxidant status in Alzheimer’s disease (AD) and to investigate the relationship between these parameters. METHODS: Patients newly diagnosed with AD were enrolled in the study. The control group consisted of age‐ and gender‐matched he...

Descripción completa

Detalles Bibliográficos
Autores principales: Yildiz, Zeynep, Eren, Nezaket, Orcun, Asuman, Münevver Gokyigit, Fatma, Turgay, Fatma, Gündogdu Celebi, Lale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444954/
https://www.ncbi.nlm.nih.gov/pubmed/34553117
http://dx.doi.org/10.1002/agm2.12173
Descripción
Sumario:OBJECTIVE: We aimed to evaluate apelin‐13 levels, total oxidant/antioxidant status in Alzheimer’s disease (AD) and to investigate the relationship between these parameters. METHODS: Patients newly diagnosed with AD were enrolled in the study. The control group consisted of age‐ and gender‐matched healthy individuals. Serum levels of apelin‐13, total antioxidant status (TAS), and total oxidant status (TOS) were measured. Oxidative stress index was calculated (TOS/TAS) for each participant. RESULTS: We reported that serum apelin‐13 and TAS values were significantly lower in the AD group compared with controls, and they found a fair but insignificant relationship between Apelin‐13 and TAS values. CONCLUSION: According to our results, we suggested that insufficient apelin‐13 and TAS levels may contribute to the pathogenesis of AD.

Ejemplares similares